The filing contains early-stage pipeline news with no clinical data or financial disclosures. The upcoming Q2 2026 earnings call on August 20 is the next catalyst to watch for revenue/cash position updates. Until then, the announcement lacks material near-term catalyst.
Price Chart
Executive Summary
Evaxion announced a pipeline refocusing, adding a new glioblastoma vaccine program (EVX-05) in collaboration with Duke University while discontinuing the EVX-03 program. The company reiterated its cash runway into H2 2027 and stated EVX-05 costs are within existing budgets, but no financial figures or clinical data were provided. This is a preclinical-stage pipeline update with no near-term revenue or catalyst data.
Key Facts
- New glioblastoma vaccine program EVX-05 announced, off-the-shelf, targeting ERV-derived antigens, in collaboration with Duke University.
- Evaxion maintains cash runway into the second half of 2027; EVX-05 costs are within existing budgets.
- EVX-03 program discontinued.
- No financial figures, clinical data, or guidance were provided in this filing.
- Q2 2026 earnings call/webcast scheduled for August 20, 2026.
Financial Impact
No financial impact data disclosed in the filing. Cash runway into H2 2027 reiterated; pipeline refocus with no incremental cost.
Risk Factors
- No clinical data for EVX-05; program is at preclinical optimization stage.
- Discontinuation of EVX-03 removes a pipeline asset.
- Pre-revenue clinical-stage biotech with high cash burn; cash runway into H2 2027 provides limited visibility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005577 |
| Document: f6k_081726.htm | 0001171843-26-005577 |
| Document: 0001171843-26-005577-index-headers.html | 0001171843-26-005577 |
| Document: 0001171843-26-005577-index.html | 0001171843-26-005577 |
| Document: 0001171843-26-005577.txt | 0001171843-26-005577 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access